Skip to content

US · PODD · MEDICAL - DEVICES

Insulet Corp. (PODD) intrinsic value and stock valuation

$133.17as of 2026-11-21 · Mkt cap 9.23B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Insulet Corp. DCF and intrinsic value

InvestorsCraft values PODD with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from PODD’s statements →

Insulet Corp. Graham Number

Graham Number: $41.26d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices Acton, MA 01720 insulet.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$2.71B+24.5% 5y CAGRd
20112025
Net income
$247.1M+105.2% 5y CAGRd
20112025
Free cash flow
$377.7M
20112025
Total equity
$1.52B+20.2% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$2.71B$2.07B$1.7B$1.31B$1.1B
Operating income$473.8M$308.9M$220M$37.6M$126M
Net income$247.1M$418.3M$206.3M$4.6M$16.8M
EPSd$3.44M$5.66M$2.8M$65.8K$245K
Operating cash flow$569.3M$430.3M$145.7M$119M-$-68.1M
Capital expenditure-$-191.6M-$-124.9M-$-75.6M-$-157.3M-$-122.7M
Free cash flow$377.7M$305.4M$70.1M-$-38.3M-$-190.8M
Total assets$3.19B$3.09B$2.59B$2.25B$2.05B
Total debt$1.05B$1.42B$1.45B$1.43B$1.29B
Net debt$334.7M$468.6M$798.1M$808.9M$494.9M
Total equity$1.52B$1.21B$732.7M$476.4M$556.3M
Cash and short-term investments$716.1M$953.4M$704.2M$674.7M$791.6M
Income statement
20252024202320222021
Revenue$2.71B$2.07B$1.7B$1.31B$1.1B
Cost of revenue$768.2M$625.9M$537.2M$499.7M$346.7M
Gross profit$1.94B$1.45B$1.16B$805.6M$752.1M
Research and development expenses$301.1M$219.6M$205M$180.2M$160.1M
Selling, general and administrative expenses$1.17B$917.2M$734.9M$587.8M$466M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$1.47B$1.14B$939.9M$768M$626.1M
Cost and expenses$2.23B$1.76B$1.48B$1.27B$972.8M
Interest income$34.7M$39.5M$28.6M$9.3M$500K
Interest expense$79.7M$42.7M$36.2M$36M$61.7M
Depreciation and amortization$113.1M$80.8M$72.8M$63.2M$57.4M
Ebitda$532.3M$423.7M$323.6M$109M$139.6M
Operating income$473.8M$308.9M$220M$37.6M$126M
Total other income/expenses, net-$-134.3M-$-8.7M-$-5.4M-$-27.8M-$-105.5M
Income before tax$339.5M$300.2M$214.6M$9.8M$20.5M
Income tax expense$92.4M-$-118.1M$8.3M$5.2M$3.7M
Net income$247.1M$418.3M$206.3M$4.6M$16.8M
Weighted average shares outstanding$70.4M$70.1M$69.8M$69.4M$67.7M
Weighted average diluted shares outstanding$71.9M$73.9M$73.6M$69.9M$68.6M
Balance sheet
20252024202320222021
Cash and short-term investments$716.1M$953.4M$704.2M$674.7M$791.6M
Net receivables$516.9M$365.5M$359.7M$205.6M$161M
Inventory$452.6M$430.4M$402.6M$346.8M$303.2M
Total current assets$1.89B$1.87B$1.57B$1.3B$1.32B
Property, plant and equipment, net$863.2M$759.8M$692.8M$625.9M$546.4M
Goodwill and intangible assets$168.7M$150M$150.4M$127.2M$76.4M
Long-term investments$20.1M$5.5M$0.00$15M$19.3M
Total non-current assets$1.3B$1.22B$1.02B$952.3M$732.3M
Total assets$3.19B$3.09B$2.59B$2.25B$2.05B
Accounts payable$75M$19.8M$19.2M$30.8M$37.7M
Short-term debt$22.2M$85.9M$52.9M$31.1M$30.1M
Deferred revenue$14M$12M$15.4M$16.1M$3.5M
Total current liabilities$680.1M$528.4M$451.2M$364.7M$228.8M
Long-term debt$1.03B$1.34B$1.4B$1.4B$1.26B
Deferred revenue, non-current$1.5M$2M$1.9M$1.6M$1.5M
Total non-current liabilities$995.1M$1.35B$1.4B$1.41B$1.26B
Capital lease obligations$48.9M$40M$29.5M$27.4M$7.6M
Total liabilities$1.68B$1.88B$1.86B$1.77B$1.49B
Common stock$100K$100K$100K$100K$100K
Retained earnings$287.4M$40.3M-$-378M-$-584.3M-$-649.5M
Accumulated other comprehensive income (loss)$13.2M-$-13.2M$8M$20M-$-2.2M
Total equity$1.52B$1.21B$732.7M$476.4M$556.3M
Total investments$20.1M$5.5M$53.5M$65.8M$19.3M
Total debt$1.05B$1.42B$1.45B$1.43B$1.29B
Net debt$334.7M$468.6M$798.1M$808.9M$494.9M
Cash flow statement
20252024202320222021
Net income$247.1M$418.3M$206.3M$4.6M$16.8M
Depreciation and amortization$90.4M$80.8M$72.8M$63.2M$57.4M
Stock-based compensation$62.7M$69.3M$48.3M$40.9M$34.4M
Change in working capital-$-23.1M-$-17M-$-190.6M-$-2.5M-$-263.6M
Accounts receivable-$-140.2M-$-10.4M-$-154.2M-$-51.8M-$-71.3M
Inventory-$-10.6M-$-32.4M-$-53.6M-$-49.1M-$-154.4M
Accounts payable$49.2M$2.2M-$-11M-$-2.4M-$-15.6M
Net cash provided by operating activities$569.3M$430.3M$145.7M$119M-$-68.1M
Investments in property, plant and equipment-$-191.6M-$-134M-$-109.2M-$-157.3M-$-122.7M
Acquisitions, net$0.00$0.00-$-3M-$-26M$0.00
Net cash used for investing activities-$-222.7M-$-146.2M-$-119.4M-$-191.1M-$-82.7M
Common stock issued$33.9M$20.1M$26.9M$16.3M$23.5M
Common stock repurchased-$-59.6M$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-595.3M-$-28.1M-$-13.6M-$-40.3M$40.7M
Net change in cash-$-237.3M$249.2M$14.5M-$-116.7M-$-115.6M
Cash at end of period$716.1M$953.4M$704.2M$689.7M$806.4M
Operating cash flow$569.3M$430.3M$145.7M$119M-$-68.1M
Capital expenditure-$-191.6M-$-124.9M-$-75.6M-$-157.3M-$-122.7M
Free cash flow$377.7M$305.4M$70.1M-$-38.3M-$-190.8M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Insulet Corp.

        Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

        CEO
        Ashley McEvoy
        Employees
        5.4K
        Beta
        1.11

        Explore

        Frequently asked questions

        What is the intrinsic value of Insulet Corp. (PODD)?

        Insulet Corp. (PODD) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PODD undervalued?

        PODD trades at a price of $133.17 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.